- DOJ reaches largest-ever federal government settlement over auto loan discrimination
- U.S. Navy to start giving gay couples marriage benefits in Japan
- Sen. Harry Reid goes to hospital as a precaution
- Fla.’s Trey Radel exits rehab, ‘excited’ to resume congressional role
- U.S. nuclear general boozed it up, chased ‘hot women’ in Russia: report
- 45 Calif. students at one school test positive for tuberculosis exposure
- Rob Ford on women: Give them cash ‘and they are happy’
- Ku Klux Klan group holds recruitment meeting in Maryland
- Airport assassination: Mayor, 3 others killed at Manila airport
- Tea party-type lawmakers take mysterious, off-books trip to Mideast
FDA panel backs first pill to block HIV infection
Question of the Day
SILVER SPRING, MD. (AP) - The first drug shown to prevent HIV infection won the endorsement of a panel of federal advisers Thursday, clearing the way for a landmark approval in the 30-year fight against the virus that causes AIDS.
In a series of votes, a Food and Drug Administration advisory panel recommended approval of the daily pill Truvada for healthy people who are at high risk of contracting HIV, including gay and bisexual men and heterosexual couples with one HIV-positive partner.
The FDA is not required to follow the panel’s advice, though it usually does. A final decision is expected by June 15.
Gilead Sciences Inc., based in Foster City, Calif., has marketed Truvada since 2004 as a treatment for people who are infected with the virus. The medication is a combination of two older HIV drugs, Emtriva and Viread. Doctors usually prescribe it as part of a drug cocktail to repress the virus.
While panelists ultimately backed Truvada for prevention, Thursday’s 12-hour meeting highlighted a number of concerns created by the first drug to prevent HIV. In particular, the panel debated whether Truvada might lead to reduced use of condoms, the most reliable defense against HIV. The experts also questioned the drug’s effectiveness in women, who have shown much lower rates of protection in studies.
Panelists struggled to outline steps that would ensure patients take the pill every day. In clinical trials, patients who didn’t take their medication diligently were not protected, and patients in the real world are even more likely to forget than those in studies.
“The trouble is adherence, but I don’t think it’s our charge to judge whether people will take the medicine,” said Dr. Tom Giordano of Baylor College of Medicine, who voted in favor of the drug. “I think our charge is to judge whether it works when it’s taken and whether the risks outweigh the benefits.”
Panelists stressed that people should be tested to make sure they don’t have HIV before starting therapy with Truvada. Patients who already have the virus and begin taking Truvada could develop a resistance to the drug, making their disease even more difficult to treat. The experts grappled with how to protect patients while avoiding hurdles that could discourage them from seeking treatment.
“If we put up too many hoops to jump through, there will be people who don’t make it through those hoops,” said Daniel Raymond, the panel’s patient representative.
Truvada first made headlines in 2010, when government researchers showed it could prevent people from contracting HIV. A three-year study found that daily doses cut the risk of infection in healthy gay and bisexual men by 42 percent, when accompanied by condoms and counseling. Last year another study found that Truvada reduced infection by 75 percent in heterosexual couples in which one partner was infected with HIV and the other was not.
But Truvada’s groundbreaking preventive ability has exposed stark disagreements on prevention among those in the HIV community. While Truvada’s supporters say the drug is an important new option, critics worry that the drug could give users a false sense of security, and encourage risky behavior.
During the meeting’s public comment period, FDA panelists heard from more than two dozen doctors, nurses and patients who said patients would not take the drug as recommended _ every day, in addition to using condoms.
“Truvada needs to be taken every day, 100 percent of the time, and my experience as a registered nurse tells me that won’t happen,” Karen Haughey told the panel. “In my eight years, not one patient that I’ve cared for has been 100 percent adherent.”
Other speakers worried that wide scale use of Truvada would divert limited funding from more cost-effective options. Truvada sells for about $900 a month, or just under $11,000 per year. The AIDS Healthcare Foundation, which opposes approval of Truvada, estimates that 20 HIV-positive patients could be treated for the cost of treating one patient with preventive Truvada.
By John McAfee
- Breaking Fad: Alligators becoming the new pit bulls for drug dealers, cops say
- D.C. to tout Obamacare among youth waiting for Air Jordans
- Huge backlash mounts over suspension of 'Duck Dynasty' star Phil Robertson
- TARGET credit card theft swells to 40 million victims
- Special ops vets slam military benefit cuts
- Obama: 2014 will be 'breakthrough year' for U.S.
- Dems use new filibuster rules to approve DHS nominee Alejandro Mayorkas under investigation
- Obamacare 'pajamas boy' gets roundly mocked
- Citing 'unfair system,' Obama commutes sentences for 8 crack offenders
- Homeland Security helps smuggle illegal immigrant children into the U.S.
Independent voices from the The Washington Times Communities
Top 10 handguns in the U.S.
Extraordinary day at Redskins Park
White House pets gone wild!
Let it snow